United StatesSets federal 'fair prices' for prescription drugs and enforces them
It changes how prescription drugs are priced in the U.S., affecting patient costs, drug availability, company revenues, and legal enforcement.
What it does
Creates a 13‑member Prescription Drug Price Regulatory Commission to recommend a yearly “fair price” for each approved prescription drug.
Requires the HHS Secretary to publish an annual fair price for every approved prescription drug and to consider the Commission’s recommendations.
Imposes civil penalties for manufacturers who do not make drugs available at or below the published fair price and creates private and state enforcement routes plus FTC enforcement.
Gives the HHS Secretary conditional 'march-in' rights to license patents and authorizes use of the Defense Production Act to expand domestic supply when needed.
Argument forWould lower out-of-pocket prices and increase affordability by requiring published fair prices for every approved prescription drug.
Argument againstMay reduce revenue incentives for drug R&D and investment if prices are set below market returns, risking slower innovation.
Where do you stand?
Choose your position
Tell your reps
Take a position to see your representatives and ways to contact them.
Where it stands
- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Looking ahead
No hearings or votes scheduled.
History
- 2026
- May 26Introduced in HouseLatest
- May 26Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, and Financial Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.Introduced
HealthcareConsumer ProtectionGovernment & Ethics